1
|
Wu H, Ye J, Zhang M, Luo H. A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors. J Cancer 2024; 15:714-728. [PMID: 38213732 PMCID: PMC10777036 DOI: 10.7150/jca.91033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 11/28/2023] [Indexed: 01/13/2024] Open
Abstract
Recent studies have reported that HOXB-AS3 (HOXB Cluster Antisense RNA 3) is an intriguing molecule with dual functionality as a long noncoding RNA (lncRNA) and putative coding peptide in tumorigenesis and progression. The significant expression alterations of HOXB-AS3 were detected in diverse cancer types and closely correlated with clinical stage and patient survival. Furthermore, HOXB-AS3 was involved in a spectrum of biological processes in solid tumors and hematological malignancies, such as stemness, lipid metabolism, migration, invasion, and tumor growth. This review comprehensively analyzes its clinical relevance for diagnosis and prognosis across human tumors and summarizes its functional role and regulatory mechanisms in different malignant tumors, including liver cancer, acute myeloid leukemia, ovarian cancer, lung cancer, endometrial carcinoma, colon cancer, and oral squamous cell carcinoma. Overall, HOXB-AS3 emerges as a promising biomarker and novel therapeutic target in multiple human tumors.
Collapse
Affiliation(s)
- Hongze Wu
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi, China
- Department of Traditional Chinese Medicine, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang 332007, Jiangxi, China
| | - Jiarong Ye
- Nanchang University Queen Mary School, Nanchang 330038, Jiangxi, China
| | - Mengqi Zhang
- The Second Clinical Medical College, Nanchang University, Nanchang 330038, Jiangxi, China
| | - Hongliang Luo
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi, China
| |
Collapse
|
2
|
Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C, Cui J, Liang T. FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies. Front Pharmacol 2023; 14:1278056. [PMID: 38027013 PMCID: PMC10680170 DOI: 10.3389/fphar.2023.1278056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 10/11/2023] [Indexed: 12/01/2023] Open
Abstract
Drug therapy, including chemotherapy, targeted therapy, immunotherapy, and endocrine therapy, stands as the foremost therapeutic approach for contemporary human malignancies. However, increasing drug resistance during antineoplastic therapy has become a substantial barrier to favorable outcomes in cancer patients. To enhance the effectiveness of different cancer therapies, an in-depth understanding of the unique mechanisms underlying tumor drug resistance and the subsequent surmounting of antitumor drug resistance is required. Recently, F-box and WD Repeat Domain-containing-7 (FBXW7), a recognized tumor suppressor, has been found to be highly associated with tumor therapy resistance. This review provides a comprehensive summary of the underlying mechanisms through which FBXW7 facilitates the development of drug resistance in cancer. Additionally, this review elucidates the role of FBXW7 in therapeutic resistance of various types of human tumors. The strategies and challenges implicated in overcoming tumor therapy resistance by targeting FBXW7 are also discussed.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Tingting Liang
- Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China
| |
Collapse
|
3
|
Zeng R, Wang L, Zhang Y, Yang Y, Yang J, Qin Y. Exploring the immunological role and prognostic potential of PPM1M in pan-cancer. Medicine (Baltimore) 2023; 102:e32758. [PMID: 36961170 PMCID: PMC10036021 DOI: 10.1097/md.0000000000032758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 01/05/2023] [Indexed: 03/25/2023] Open
Abstract
BACKGROUND PPM1M is a member of the metal-dependent protein phosphatase family, and its role in the immunization process has not been studied in depth. In this study, we investigated the role of PPM1M in pan-cancer. METHODS Samples of cancer and normal tissues were obtained from the cancer genome atlas and genotype-tissue expression. Kaplan-Meier survival curves and Cox regression were used to analyze the effect of PPM1M on prognosis. Functional and pathway enrichment analyses were performed using the R package "clusterProfiler" to explore the role of PPM1M. The Sanger Box database was used to analyze the relationship between PPM1M and tumor immune checkpoint, tumor mutational burden, and microsatellite instability. The Tumor Immune Estimation Resource 2 database and CIBERSORT method were used to analyze the relationship between PPM1M and tumor-infiltrating immune cells. Finally, the cBioPortal database was used to analyze the genomic variation in PPM1M. RESULTS Among the variety of tumors, the expression of PPM1M was higher in normal tissues than in cancerous tissues. The expression of PPM1M is closely associated with patient prognosis, tumor immune checkpoint, tumor mutational burden, and microsatellite instability. PPM1M is closely associated with the infiltration of immune cells into the tumor microenvironment. In addition, PPM1M is involved in the regulation of several immune-related pathways. CONCLUSION In pan-cancer, PPM1M affects patient prognosis and may be a potential immunological biomarker. Furthermore, PPM1M may be a potential therapeutic target in tumor immunology.
Collapse
Affiliation(s)
- Rongruo Zeng
- Department of Health Management, The People’s Hospital of Guangxi Zhuang Autonomous Region & Research Center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, People’s Republic of China
- Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China
| | - Lulu Wang
- Department of Health Management, The People’s Hospital of Guangxi Zhuang Autonomous Region & Research Center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, People’s Republic of China
| | - Yuxu Zhang
- Department of International Medicine Services, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People’s Republic of China
| | - Ye Yang
- Department of Rehabilitation Medicine, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
| | - Jie Yang
- Department of Health Management, The People’s Hospital of Guangxi Zhuang Autonomous Region & Research Center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, People’s Republic of China
| | - Yan Qin
- Department of Health Management, The People’s Hospital of Guangxi Zhuang Autonomous Region & Research Center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, People’s Republic of China
| |
Collapse
|
4
|
Weidemann S, Noori NA, Lennartz M, Reiswich V, Dum D, Menz A, Chirico V, Hube-Magg C, Fraune C, Bawahab AA, Bernreuther C, Simon R, Clauditz TS, Sauter G, Hinsch A, Kind S, Jacobsen F, Steurer S, Minner S, Burandt E, Marx AH, Krech T, Lebok P, Büscheck F, Höflmayer D. Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors. Biomedicines 2022; 10. [PMID: 36289769 DOI: 10.3390/biomedicines10102507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 10/01/2022] [Accepted: 10/03/2022] [Indexed: 12/04/2022] Open
Abstract
As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.
Collapse
|
5
|
Abstract
Nicotinamide adenine dinucleotide (NAD+) is an important molecule that functions as a co-enzyme in numerous metabolic processes. Generated both through de novo synthesis and via salvage pathways, NAD+ is the substrate for a variety of NAD+-consuming enzymes. Among them is CD38, a cell surface ecto-enzyme widely expressed on different types of cells and endowed with the function of cADP-ribose synthases/NAD+ glycohydrolase. Surface CD38 expression is increased in different hematological and solid tumors, where it cooperates with other ecto-enzymes to produce the immunosuppressive molecule adenosine (ADO). Few studies have explored the correlation of NAD+ levels with T-cell mediated anti-tumor response in preclinical models. We therefore discuss these novel findings, examining the possible contribution of NAD+ depletion, along with ADO production, in the immunosuppressive activities of CD38 in the context of human tumors. Lastly, we discuss the use of pharmacological inhibitors of CD38 and supplementation of different NAD+ precursors to increase NAD+ levels and to boost T cell responses. Such molecules may be employed as adjuvant therapies, in combination with standard treatments, for cancer patients.
Collapse
Affiliation(s)
- Fabio Morandi
- Laboratorio Cellule Staminali Post-Natali e Terapie Cellulari, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Alberto Leonardo Horenstein
- Dipartimento Scienze Mediche, Università di Torino, Centro Ricerche Medicina Sperimentale (CeRMS) and Fondazione Ricerca Molinette Onlus, Torino, Italy
| | - Fabio Malavasi
- Dipartimento Scienze Mediche, Università di Torino, Centro Ricerche Medicina Sperimentale (CeRMS) and Fondazione Ricerca Molinette Onlus, Torino, Italy
| |
Collapse
|
6
|
Lang H, Béraud C, Bethry A, Danilin S, Lindner V, Coquard C, Rothhut S, Massfelder T. Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma. Oncotarget 2018; 7:59336-59359. [PMID: 27449081 PMCID: PMC5312316 DOI: 10.18632/oncotarget.10659] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Accepted: 07/05/2016] [Indexed: 12/15/2022] Open
Abstract
The objective of the present work was to establish a large panel of preclinical models of human renal cell carcinoma (RCC) directly from patients, faithfully reproducing the biological features of the original tumor. RCC tissues (all stages/subtypes) were collected for 8 years from 336 patients undergoing surgery, xenografted subcutaneously in nude mice, and serially passaged into new mice up to 13 passages. Tissue samples from the primary tumor and tumors grown in mice through passages were analyzed for biological tissue stability by histopathology, mRNA profiling, von Hippel-Lindau gene sequencing, STR fingerprinting, growth characteristics and response to current therapies. Metastatic models were also established by orthotopic implantation and analyzed by imagery. We established a large panel of 30 RCC models (passage > 3, 8.9% success rate). High tumor take rate was associated with high stage and grade. Histopathologic, molecular and genetic characteristics were preserved between original tumors and case-matched xenografts. The models reproduced the sensitivity to targeted therapies observed in the clinic. Overall, these models constitute an invaluable tool for the clinical design of efficient therapies, the identification of predictive biomarkers and translational research.
Collapse
Affiliation(s)
- Hervé Lang
- Department of Urology, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, 67091 France
| | - Claire Béraud
- UROLEAD SAS, School of Medicine, Strasbourg, 67085 France
| | - Audrey Bethry
- UROLEAD SAS, School of Medicine, Strasbourg, 67085 France
| | - Sabrina Danilin
- INSERM U1113, Section of Cell Signalisation and Communication in Kidney and Prostate Cancer, University of Strasbourg, School of Medicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, 67085 France
| | - Véronique Lindner
- Department of Pathology, Hôpitaux Universitaires de Strasbourg, Hôpital de Strasbourg-Hautepierre, Strasbourg, 67200 France
| | - Catherine Coquard
- INSERM U1113, Section of Cell Signalisation and Communication in Kidney and Prostate Cancer, University of Strasbourg, School of Medicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, 67085 France
| | - Sylvie Rothhut
- INSERM U1113, Section of Cell Signalisation and Communication in Kidney and Prostate Cancer, University of Strasbourg, School of Medicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, 67085 France
| | - Thierry Massfelder
- INSERM U1113, Section of Cell Signalisation and Communication in Kidney and Prostate Cancer, University of Strasbourg, School of Medicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, 67085 France
| |
Collapse
|
7
|
Tcherkassova J, Tsurkan S, Smirnova G, Borisova J, Moro R, Treshalina H. Binding characterization of the targeting drug AIMPILA to AFP receptors in human tumor xenografts. Tumour Biol 2017; 39:1010428317734815. [PMID: 28990489 DOI: 10.1177/1010428317734815] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The main objective of this study was the characterization of preclinical tumor models based on their expression of alpha-fetoprotein receptor (RECAF) for targeting cancer cells with a new non-covalent complex (AIMPILA) containing alpha-fetoprotein as the carrier and Atractyloside as an apoptosis-inducing agent. For that purpose, we measured the amount of RECAF in the homogenates of the grafted tumors T47D and SW620 and in HepG2 cell extracts. We also determined the alpha-fetoprotein binding specificity of the targeting drug AIMPILA using a solid-phase chemiluminescent assay with AIMPILA-Acrdidinium. We found that RECAF is practically absent from healthy mice tissues (100 Units/mg) where in malignant cells, the amount of alpha-fetoprotein receptors follows this order: T47D (9152 Units/mg) > HepG2 (4865 Units/mg) > SW620 (2839 Units/mg). This agrees with our findings regarding AIMPILA-induced tumor growth inhibition (T47D (T/C = 22%) > HepG2 (T/C = 51%) > SW620 (T/C = 70%), where T/C is the ratio of tumor volume in treated vs control animals). Our results demonstrate that the therapeutic response to the targeting drug AIMPILA strongly depends on the RECAF expression by human tumors and confirms the choice of the tumor models used for an AIMPILA preclinical study.
Collapse
Affiliation(s)
| | - Sergei Tsurkan
- 1 Pharmaceutical Research Center, PharmAccess, Moscow, Russian Federation
| | - Galina Smirnova
- 2 Federal State Budgetary Institution, N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of Russian Federation
| | - Julia Borisova
- 2 Federal State Budgetary Institution, N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of Russian Federation
| | - Ricardo Moro
- 3 Pacific Biosciences Research Center, Richmond, BC, Canada
| | - Helen Treshalina
- 2 Federal State Budgetary Institution, N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of Russian Federation
| |
Collapse
|
8
|
Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, Beltjens F, Ghiringhelli F, Ladoire S. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology 2015; 5:e1054598. [PMID: 27057426 DOI: 10.1080/2162402x.2015.1054598] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 05/17/2015] [Accepted: 05/20/2015] [Indexed: 01/12/2023] Open
Abstract
Tumor-infiltrating T and B lymphocytes could have the potential to affect cancer prognosis. The objective of this study was to investigate the prognostic significance of tumor infiltration by CD8 and CD4 T cells, and B lymphocytes in patients with localized gastric cancer. In a retrospective cohort of 82 patients with localized gastric cancer and treated by surgery we quantitatively assessed by immunohistochemistry on surgical specimen, immune infiltrates of IL-17+, CD8+, Foxp3+, Tbet+ T cells and CD20+ B cells both in the tumor core and at the invasive margin via immunohistochemical analyses of surgical specimens. We observed that CD8+ and IL17+ T-cell densities were not significantly associated with gastric cancer prognosis. In contrast, high infiltration of Tbet+ T cells, high numbers of CD20+ B-cell follicles, and low infiltration of Foxp3+ T cells, were associated with better relapse-free survival. Interestingly, treatment with neoadjuvant chemotherapy or histological tumor type (diffuse versus intestinal) did not influence type and density of immune infiltrates or their prognostic value. Immunohistochemical analysis of the gastric cancer stromal microenvironment revealed organized T and B cell aggregates, with strong structural analogies to normal secondary lymphoid organs and which could be considered as tertiary lymphoid structures. Using transcriptomic data from an independent cohort of 365 localized gastric cancer, we confirmed that a coordinated Th1, and B cell stromal gene signature is associated with better outcome. Altogether, these data suggest that tumor infiltration by B and Th1 T cells could affect gastric cancer prognosis and may be used to better define the outcome of patients with localized gastric cancer.
Collapse
Affiliation(s)
- Audrey Hennequin
- Department of Medical Oncology Center Georges François Leclerc; Dijon, France; Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France
| | - Valentin Derangère
- Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France; Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc; Dijon, France
| | - Romain Boidot
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France; Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc; Dijon, France
| | - Lionel Apetoh
- Department of Medical Oncology Center Georges François Leclerc; Dijon, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France; Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc; Dijon, France
| | - Julie Vincent
- Department of Medical Oncology Center Georges François Leclerc ; Dijon, France
| | - David Orry
- Department of Surgical Oncology. Center Georges François Leclerc ; Dijon, France
| | - Jean Fraisse
- Department of Surgical Oncology. Center Georges François Leclerc ; Dijon, France
| | - Sylvain Causeret
- Department of Surgical Oncology. Center Georges François Leclerc ; Dijon, France
| | - François Martin
- Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France
| | - Laurent Arnould
- Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc ; Dijon, France
| | - Françoise Beltjens
- Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc ; Dijon, France
| | - François Ghiringhelli
- Department of Medical Oncology Center Georges François Leclerc; Dijon, France; Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France; Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc; Dijon, France
| | - Sylvain Ladoire
- Department of Medical Oncology Center Georges François Leclerc; Dijon, France; Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 866; Dijon, France; Department of Biology and Pathology of Tumors. Plateform of Genetic; Immunology and Histology of Solid Tumors; Centre Georges-François Leclerc; Dijon, France; Faculté des Sciences de Santé; Université de Bourgogne; Dijon, France
| |
Collapse
|
9
|
Zhang Y, Hiroshima Y, Ma H, Zhang N, Zhao M, Hoffman RM. Complementarity of variable-magnification and spectral-separation fluorescence imaging systems for noninvasive detection of metastasis and intravital detection of single cancer cells in mouse models. Anticancer Res 2015; 35:661-667. [PMID: 25667443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Imaging of tumor growth, progression and metastasis with fluorescent proteins in mouse models is a powerful technology. A limit to fluorescent-protein imaging has been for non-invasive deep-seated tumors, such as those in the lung. In the present study, the Maestro spectral-separation fluorescence imaging system and the OV100 variable-magnification imaging system were compared for noninvasive detection of metastasis in fluorescent protein-expressing orthotopic lung, liver, pancreas, and colon cancer in nude mouse tumor models, as well as for intravital single-cell imaging. Sensitivity, multispectral capability, contrast, and single cell resolution were investigated. The Maestro system outperformed the OV100 for noninvasive imaging of primary and metastatic tumors. The Maestro system detected brain tumor metastasis five days earlier than did the OV100. The Maestro had greater depth of detection compared with the OV100. By separating skin and food autofluorescence, the Maestro provided high-contrast images. The Maestro system was able to produce composite images with more unmixed components and detected more different color signals simultaneously than did the OV100. However, the OV100 system had higher resolution and was able to detect single cells in vivo unlike the Maestro. The present study demonstrates that the two instruments are complementary for imaging of all stages of cancer in mice, including single-cell trafficking and the superiority of in vivo fluorescent-protein imaging over luciferase imaging.
Collapse
Affiliation(s)
- Yong Zhang
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A
| | - Yukihiko Hiroshima
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A. Department of Surgery, University of California, San Diego, CA, U.S.A. Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Huaiyu Ma
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A
| | - Nan Zhang
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A
| | - Ming Zhao
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A
| | - Robert M Hoffman
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA, U.S.A. Department of Surgery, University of California, San Diego, CA, U.S.A.
| |
Collapse
|
10
|
Shi Y, Amin K, Sato BG, Samuelsson SJ, Sambucetti L, Haroon ZA, Laderoute K, Murphy BJ. The metal-responsive transcription factor-1 protein is elevated in human tumors. Cancer Biol Ther 2010; 9:469-76. [PMID: 20087061 PMCID: PMC3039317 DOI: 10.4161/cbt.9.6.10979] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
We previously identified metal-responsive transcription factor-1 (MTF-1) as a positive contributor to mouse fibrosarcoma growth through effects on cell survival, proliferation, tumor angiogenesis and extracellular matrix remodeling. In the present study, we investigated MTF-1 protein expression in human tissues by specific immunostaining of both normal and tumor tissue samples. Immunohistochemical (IHC) staining of a human tissue microarray (TMA), using a unique anti-human MTF-1 antibody, indicated constitutive MTF-1 expression in most normal tissues, with liver and testis displaying comparatively high levels of expression. Nevertheless, MTF-1 protein levels were found to be significantly elevated in diverse human tumor types, including breast, lung and cervical carcinomas. IHC analysis of a separate panel of full-size tissue sections of human breast cancers, including tumor and normal adjacent, surrounding tissue, confirmed and extended the results of the TMA analysis. Taken with our previous findings, this new study suggests a role for MTF-1 in human tumor development, growth or spread. Moreover, the study suggests that MTF-1 could be a novel therapeutic target that offers the opportunity to manipulate metal or redox homeostasis in tumor cells.
Collapse
Affiliation(s)
- Yihui Shi
- Biosciences Division, SRI International, Menlo Park, CA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Nowsheen S, Wukovich RL, Aziz K, Kalogerinis PT, Richardson CC, Panayiotidis MI, Bonner WM, Sedelnikova OA, Georgakilas AG. Accumulation of oxidatively induced clustered DNA lesions in human tumor tissues. Mutat Res 2009; 674:131-6. [PMID: 18948225 PMCID: PMC6944316 DOI: 10.1016/j.mrgentox.2008.09.010] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2008] [Accepted: 09/23/2008] [Indexed: 02/05/2023]
Abstract
Increased levels of oxidatively induced DNA damage have been reported in various cases of human pathogenesis like age-related and chronic diseases. Advances in experimental carcinogenesis associate high oxidative stress with genome instability and oncogenic transformation. Cancer biomarkers are helpful for early tumor diagnostics, prediction of tumor development, and analysis of individual tumors' response to therapy as well as recurrence. The repair resistant oxidatively induced clustered DNA lesions (OCDLs) could serve as a common indicator of oxidative stress in human malignant cells or tissues. To test this hypothesis, we assessed the levels of endogenous OCDLs in several human tumor and adjacent normal tissues from patients with liver, ovary, kidney, breast and colon cancer. These tumor tissues have already been shown to accumulate higher endogenous levels of gamma-H2AX foci. For the detection of clustered DNA lesions we used the human repair enzymes APE1, OGG1 and NTH1 as well as the Escherichia coli homologue Endonuclease III. In the majority of cases we detected higher levels of OCDLs in tumor vs. normal tissues but not always with a statistically significant difference and not with uniform tissue dependence. These data suggest for the first time the importance of endogenous non-DSB clusters in human cancer and their potential use as cancer biomarkers.
Collapse
Affiliation(s)
- Somaira Nowsheen
- Department of Biology, Thomas Harriot College of Arts and Sciences, East Carolina University, Greenville, NC 27858, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol Immunother 1998; 46:21-4. [PMID: 9520288 PMCID: PMC11037336 DOI: 10.1007/s002620050455] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A novel biodegradable poly(lactic acid) microsphere formulation was evaluated for in vivo cytokine immunotherapy of cancer in a human tumor xenograft/ severe combined immunodeficiency (SCID) mouse model. Co-injection of interleukin-2 (IL-2)-loaded microspheres with tumor cells into a subcutaneous site resulted in the complete suppression of tumor engraftment in 80% of animals. In contrast, bovine-serum-albumin(BSA)-loaded particles or bolus injections of poly(ethylene glycol)/IL-2 were ineffective in preventing tumor growth. The antitumor effect of IL-2 released by the microspheres was shown to be mediated by the mouse natural killer cells. This is the first evidence that the rejection of human tumor xenografts can be provoked by the sustained in vivo delivery of IL-2 from biodegradable microspheres. The use of poly(lactic acid) microspheres to deliver cytokines to the tumor environment could provide a safer and simpler alternative to gene therapy protocols in the treatment of cancer.
Collapse
Affiliation(s)
- N K Egilmez
- Department of Molecular Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Wang P, Vánky F, Klein E. Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas and sarcomas. Cancer Immunol Immunother 1991; 33:65-9. [PMID: 2021960 PMCID: PMC11038337 DOI: 10.1007/bf01742531] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/1990] [Accepted: 10/17/1990] [Indexed: 12/29/2022]
Abstract
By one-dimension isoelectric focusing we analysed the major histocompatibility complex class I antigen expression on human tumours. Blood lymphocytes of the patients, processed in parallel, served as a basis for comparison. The prerequisite for the analysis is the preparation of metabolically active tumour cell suspensions devoid of significant leucocyte contamination. The method was found to be suitable for study of the expression of HLA alleles on ex vivo tumour cells and allowed the detection of changes imposed by in vitro treatment with interferon gamma and tumour necrosis factor alpha.
Collapse
Affiliation(s)
- P Wang
- Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
| | | | | |
Collapse
|
14
|
Jagarlamoody SM, Aust JC, Tew RH, McKhann CF. In vitro detection of cytotoxic cellular immunity against tumor-specific antigens by a radioisotopic technique. Proc Natl Acad Sci U S A 1971; 68:1346-50. [PMID: 4331089 PMCID: PMC389186 DOI: 10.1073/pnas.68.6.1346] [Citation(s) in RCA: 78] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
[(3)H]Thymidine-labeled tumor cells are used to evaluate the cytotoxic cellular immune response against tumor-specific antigens; the loss of label due to destruction and detachment of target cells from the surface of the culture vessel is measured. Spleen cells from mice immunized against Moloney virus-induced rhabdomyosarcoma specifically destroyed the sarcoma cells, while cells from normal syngeneic mice did not. Peripheral blood lymphocytes from patients with malignant tumors were specifically cytotoxic to autologous tumor cells and to allogeneic tumor cells histopathologically identical to the autologous tumor, but not to autologous nonmalignant fibroblasts, or to allogeneic tumor cells from a histologically dissimilar tumor. Serum from the same patients specifically protected autologous tumor cells from lymphocyte cytotoxicity. This serum-mediated protection of tumor cells against autologous cellular immunocytotoxicity also extended to histologically identical allogeneic tumor cells. Cross-reactivity of anti-tumor cellular immunocytotoxicity in vitro, and its "blocking" by autologous serum, strongly suggest the presence of common tumor antigens. The antagonism demonstrated in vitro between serum and cellular immunity may explain the continued growth of malignant tumors in the face of demonstrable cellular immunity.
Collapse
|